drugset / Trial / NCT07559370
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
Timeline
- Start
- 2026-01-20
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 260 mg/m2 | — |
| Subject | Imatinib | Small molecule | 340 mg/m2 | — |
| Subject | Imatinib | Small molecule | 400 mg | — |
| Subject | Imatinib | Small molecule | 600 mg | — |
| Comparator | Artemether | Small molecule | — | — |
| Comparator | lumefantrine | Small molecule | — | — |